Oncology Institute (TOI) Cash from Investing Activities (2020 - 2026)

Oncology Institute has reported Cash from Investing Activities for 7 years, with the latest figure at -$1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 415.84% year-over-year to -$1.0 million; the trailing twelve-month figure through Mar 2026 stood at -$3.9 million (down 114.7% YoY), and the FY2025 full-year result was -$3.1 million, down 106.65% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$1.0 million, up from -$1.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $24.9 million in Q2 2023, with the low at -$87.8 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$1.6 million across 5 years, with a median of -$604000.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 9139.89% — and 2023, when it jumped 1936.43%.
• Oncology Institute's Cash from Investing Activities stood at -$32.6 million in 2022, then jumped by 135.7% to $11.6 million in 2023, then tumbled by 115.09% to -$1.8 million in 2024, then surged by 39.6% to -$1.1 million in 2025, then grew by 1.7% to -$1.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$1.0 million (Q1 2026), -$1.1 million (Q4 2025), and -$604000.0 (Q3 2025), per Business Quant data.